Zynerba stock price sinks again after mixed results from synthetic cannabinoid study

The company plans to continue developing the new drug candidate as a therapy for patients with osteoarthritis.

Source: bizjournals.com Health Care:Biotechnology headlines - August 15, 2017 Category: Biotechnology Authors: John George Source Type: news